Healthcare Jul 07, 2021 03:24 PM (GMT+8) · EqualOcean
As of 3 p.m. today, BOC fund disclosed the second quarterly report of nine products, including one flexible configuration product, two commodity based products and six debt based products. Among them, the net asset value of Bank of China Healthcare fund managed by Liu Xiao reached 1.264 billion yuan (A / C combined calculation) at the end of the second quarter, with a growth rate of 17.88% in the quarter. Compared with the previous quarter, Beida pharmaceutical, Aier ophthalmology and Lizhu group were newly added to the top ten heavy position stocks of the fund; And Yunnan Baiyao increased its position by 208500 shares, which is the largest position of the fund; Changchun hi tech, Zhifei biology, humanwell medicine, etc. withdrew from the top ten heavy position stocks. Fund managers said that their positions focused on innovative drugs, cro / cdmo and other industry leaders, and focused on the rise of domestic life technology industry supply chain.